{
    "clinical_study": {
        "@rank": "166579", 
        "arm_group": {
            "arm_group_label": "HBVAXPRO Challenge dose", 
            "arm_group_type": "Experimental", 
            "description": "HBVAXPRO 5\u00b5g"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the  immune response to Hepatitis B virus in children who have been primed with\n      HEXAVAC or INFANRIX HEXA 10 years ago."
        }, 
        "brief_title": "Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO in Healthy Children Vaccinated 10 Years Ago With 3 Doses of HEXAVAC or INFANRIX HEXA", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Virus Diseases", 
            "Hepatitis B"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Virus Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy child\n\n          -  Child vaccinated with 3 doses of HEXAVAC or 3 doses of INFANRIX HEXA as infant\n\n          -  Child vaccinated with the third dose of HEXAVAC or INFANRIX HEXA at least 10 years\n             prior to challenge dose\n\n        Exclusion Criteria:\n\n          -  Receipt of more than 3 doses of any Hepatitis B containing vaccine\n\n          -  History of clinical diagnosis of infection due to Hepatitis B\n\n          -  History or current close contact with known carriers of Hepatitis B virus\n\n          -  Prior known sensitivity or allergy to any component of HBVAXPRO\n\n          -  Chronic illness / medical condition that could interfere with study conduct or\n             completion\n\n          -  Coagulation disorder that would contraindicate intramuscular injection\n\n          -  Subject is pregnant\n\n          -  Receipt of corticosteroids for more than 14 days in the 30 days prior to study\n\n          -  Receipt of Immunoglobulins, blood or blood-derived products in the 3 months prior to\n             study\n\n          -  Planned participation in another clinical study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "12 Years", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "750", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02012998", 
            "org_study_id": "HXV02C", 
            "secondary_id": "2013-001602-28"
        }, 
        "intervention": {
            "arm_group_label": "HBVAXPRO Challenge dose", 
            "description": "0.5mL intramuscular injection", 
            "intervention_name": "HBVAXPRO 5\u00b5g", 
            "intervention_type": "Biological", 
            "other_name": "Hepatitis B vaccine (rDNA)"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bologna", 
                        "country": "Italy"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 004"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cagliari", 
                        "country": "Italy"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 009"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Capannori", 
                        "country": "Italy"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 005"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiavari", 
                        "country": "Italy"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 003"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Latisana", 
                        "country": "Italy"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 002"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Massafra", 
                        "country": "Italy"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 008"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nocera Inferiore", 
                        "country": "Italy"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 006"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ragusa", 
                        "country": "Italy"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 010"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salerno", 
                        "country": "Italy"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 007"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sassari", 
                        "country": "Italy"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 001"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Controlled, Multi-centre Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO to Explore the Anamnestic Immune Response in Healthy Children Vaccinated 10 Years Ago With a Primary Series (3 Doses) of Either HEXAVAC or INFANRIX HEXA", 
        "overall_contact": {
            "email": "clinicaldevelopment@spmsd.com", 
            "last_name": "Florence BOISNARD, PhD"
        }, 
        "overall_contact_backup": {
            "email": "clinicaldevelopment@spmsd.com", 
            "last_name": "Marie WEHRLEN-GRANDJEAN, MD"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of subjects with an anti-hepatitis B concentration \u226510 mIU/mL", 
            "safety_issue": "No", 
            "time_frame": "One month after the challenge dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02012998"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of subjects with an anti-hepatitis B concentration \u226510 mIU/mL", 
                "safety_issue": "No", 
                "time_frame": "Prior to challenge dose (At Day 0 prior to administration of the challenge dose)"
            }, 
            {
                "measure": "Solicited injection-site adverse reactions and pyrexia", 
                "safety_issue": "Yes", 
                "time_frame": "Day 0 to day 4 after vaccination"
            }, 
            {
                "measure": "Unsolicited injection-site adverse reactions and systemic adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Day 0 to day 14 after vaccination"
            }, 
            {
                "measure": "Serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From signature of the informed consent to the last visit of the subject, an expected average of one month"
            }
        ], 
        "source": "Sanofi Pasteur MSD", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi Pasteur MSD", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}